Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
9/16/2026
Impact: 75
Healthcare
Twist Bioscience Corporation (NASDAQ: TWST) has entered into an agreement with Eli Lilly's TuneLab, an AI/ML drug discovery platform, to provide antibody characterization data services. This collaboration aims to enhance biotech innovation by allowing companies to utilize AI-driven prediction models based on Eli Lilly's extensive research data. Following the announcement, Twist's stock rose 5.79% to $146.09, nearing its 52-week high of $155.44.
AI summary, not financial advice
Share: